Article

Anemic RA and Osteoarthritis Patients Stay at Hospitals Longer

Arthritis patients that are also anemic stay at hospitals longer, undergo more procedures, and have higher hospitalization costs compared to non-anemic arthritis patients, according to a study carried out in public hospitals in France.

Arthritis patients that are also anemic stay at hospitals longer, undergo more procedures, and have higher hospitalization costs compared to non-anemic arthritis patients, according to a study carried out in public hospitals in France.

The study, published in the BMC Geriatrics, was designed to investigate associations between health care resource utilization in arthritis patients with and without concomitant anemia in a secondary setting.

The retrospective cohort study examined data on secondary care activity in 2001 from the Programme de Medicalisation des Systemes d’Information database. The team identified two cohorts using ICD-10 codes. One cohort was made up of diagnoses arthritis patients with diagnosed concomitant anemia. The other group consisted of arthritis patients without anemia.

The team found that there were s little more than 300,000 hospitalizations for patients with arthritis only and 2,744 for those with concomitant anemia. Seventy percent of those with concomitant anemia were in public hospitals, while there were only 53.5% of arthritis-only patients staying at these hospitals.

Those without anemia were also younger. Those with concomitant anemia/arthritis only had a mean length of stay of 11.91 days in public hospitals and 10.68 in private hospitals.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.